Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) have been given an average recommendation of “Buy” by the six analysts that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have updated their coverage on […]
More Stories
Rachel Zegler Shines in Disney’s ‘Snow White’ Live-Action Remake
Disney’s latest live-action remake, “Snow White,” directed by Marc Webb, premiered on March 21, 2025, sparking discussions and debates among...
JPMorgan Chase & Co. (NYSE:JPM) Shares Acquired by AGF Management Ltd.
AGF Management Ltd. increased its holdings in shares of JPMorgan Chase & Co. (NYSE:JPM – Free Report) by 9.2% during...
HighTower Advisors LLC Increases Stock Holdings in MongoDB, Inc. (NASDAQ:MDB)
HighTower Advisors LLC increased its holdings in shares of MongoDB, Inc. (NASDAQ:MDB – Free Report) by 2.0% during the 4th...
HighTower Advisors LLC Grows Holdings in Science Applications International Co. (NYSE:SAIC)
HighTower Advisors LLC lifted its stake in Science Applications International Co. (NYSE:SAIC – Free Report) by 3.3% during the 4th...
Unity Software Inc. (NYSE:U) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank
Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Unity Software Inc. (NYSE:U – Free Report) by 3.7% during the 4th...
AlphaQuest LLC Reduces Stock Position in MicroStrategy Incorporated (NASDAQ:MSTR)
AlphaQuest LLC lessened its stake in MicroStrategy Incorporated (NASDAQ:MSTR – Free Report) by 79.4% in the fourth quarter, according to...